Chemours CC Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.82B+0.5% | $5.81B+0.4% | $5.84B+0.8% | $5.85B+1.1% | $5.79B-1.7% | ||
| $4.94B+5.3% | $4.91B+5.7% | $4.83B+3.6% | $4.79B+2.6% | $4.69B+0.5% | ||
| $878M-19.8% | $902M-21.1% | $1.01B-10.7% | $1.07B-4.9% | $1.1B-10.4% | ||
| 15.1%-3.8pp | 15.5%-4.2pp | 17.3%-2.2pp | 18.2%-1.2pp | 18.9%-1.8pp | ||
| $107M-0.9% | $108M-0.9% | $107M-1.8% | $110M+1.9% | $108M-1.8% | ||
| $823M+40.9% | $799M+33.6% | $839M+29.7% | $854M+26.5% | $584M-55.1% | ||
| $969M+15.8% | $966M+17.4% | $1.01B+15.2% | $1.12B+21.1% | $837M-46.0% | ||
| $272M+1.9% | $269M+1.9% | $268M+3.1% | $268M+8.5% | $267M+16.6% | ||
| $43M— | $26M— | —— | —— | —— | ||
| -$299M-887% | -$277M-356% | -$209M-681% | -$279M-444% | $38M+109% | ||
| —— | —— | $140M+1,177% | $148M+1,333% | $26M+133% | ||
| -$410M-3,517% | -$386M-644% | -$350M-647% | -$428M-496% | $12M+104% | ||
| -7%-7.3pp | -6.6%-7.9pp | -6%-7.1pp | -7.3%-9.2pp | 0.2%+5.8pp | ||
| -$2.72-4,633% | -$2.56-669% | -$2.33-668% | -$2.86-503% | $0.06+103% | ||
| $304M-50.5% | $332M-50.0% | $392M-33.6% | $315M-49.6% | $614M+463% | ||
| 5.2%-5.4pp | 5.7%-5.8pp | 6.7%-3.5pp | 5.4%-5.4pp | 10.6%+8.8pp | ||
| -$27M-109% | -$8M-102% | $59M-80.1% | -$11M-103% | $305M+259% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Chemours's revenue?
- Chemours (CC) generated $5.8B in revenue over the trailing twelve months, up 0.5% year over year.
- Is Chemours profitable?
- Chemours is not currently profitable: it reported a net loss of $410.0M over the trailing twelve months, a -7.0% net margin.
- What is Chemours's earnings per share?
- Chemours's diluted EPS over the trailing twelve months is $-2.72.
- Where does Chemours's income statement data come from?
- Every line is extracted from Chemours's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
